Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK

被引:0
|
作者
Rothnie, Kieran J. [1 ,7 ]
Numbere, Beade [1 ]
Gelwicks, Steven [2 ]
Lu, Yifei [1 ,3 ]
Sharma, Raj [4 ]
Compton, Chris [4 ]
Ismaila, Afisi S. [2 ,5 ]
Quint, Jennifer K. [6 ]
机构
[1] GSK, Value Evidence & Outcomes, R&D Global Med, London, England
[2] GSK, Value Evidence & Outcomes, R&D Global Med, Collegeville, PA USA
[3] Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC USA
[4] GSK, Global Med, London, England
[5] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[6] Imperial Coll London, Natl Heart & Lung Inst, London, England
[7] GSK, Value Evidence & Outcomes, R&D Global Med, 980 Great West Rd, Brentford TW8 9GS, Middlesex, England
关键词
COPD; CPRD; exacerbation; GOLD A/B; risk factor; UK; OBSTRUCTIVE PULMONARY-DISEASE; HEALTH-CARE; PREDICTION; OUTCOMES;
D O I
10.2147/COPD.S413947
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Purpose: Risk factors for exacerbations of chronic obstructive pulmonary disease (COPD) have been previously characterized for patients with more severe cases of COPD. It is unclear how the risk of first exacerbation may best be identified in patients with less severe disease. This study investigated risk factors for first exacerbation among English patients with COPD classified as Global Initiative for Chronic Obstructive Lung Disease (GOLD) group A or B. Patients and Methods: A retrospective cohort study using data from the UK Clinical Practice Research Datalink (CPRD) AURUM linked to Hospital Episode Statistics. Patients with COPD aged >= 35 years and classified as GOLD group A or B (2020 criteria) from January 2013-December 2019 were eligible. Patients were required to have 24 months history in CPRD (baseline). Two cohorts were defined: cohort 1 included patients with no severe exacerbations during baseline; cohort 2 included patients with no moderate or severe exacerbations during baseline. Risk factors associated with severe, or combined moderate and severe exacerbation were examined for up to 5 years of follow-up. Results: Overall, 194,948 patients were included in cohort 1 (mean age 66.2 years; 55.2% male), and 148,396 patients in cohort 2 (mean age 66.1 years; 56.6% male). Identified risk factors for exacerbation (and associated 1-year absolute risk of severe, or combined moderate and severe exacerbation, respectively) included: Medical Research Council dyspnea scale score (15.9%/28.4%); COPD Assessment Test score (9.6%/25.3%); GOLD grade of airflow limitation (forced expiratory volume in 1 second % predicted; 13.6%/27.5%); and lung cancer (8.1%/23.6%). After adjustment for risk factors, these factors remained independently associated with severe exacerbation at 1, 3, and 5 years of follow-up. Conclusion: The identified risk factors may aid physicians in the early recognition of patients with COPD classified as GOLD group A or B at risk of first exacerbation.
引用
收藏
页码:2673 / 2685
页数:13
相关论文
共 50 条
  • [1] Identifying risk of first COPD exacerbation in COPD patients in GOLD group A/B in the UK
    Rothnie, K.
    Gelwicks, S.
    Numbere, B.
    Lu, Y.
    Sharma, R.
    Compton, C.
    Ismaila, A.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [2] Risk Factors Associated with Mortality of COPD Patients Hospitalised for Exacerbation
    Niksarlioglu, Elif Yelda
    Arsava, Begum Ergan
    Demir, Ahmet Ugur
    Iskit, Arzu Topeli
    Coplu, Lutfi
    TURKISH THORACIC JOURNAL, 2013, 14 (04) : 134 - 140
  • [3] Prevalence of coronary artery diseases among COPD patients with more symptoms and low risk of exacerbation (GOLD B) in Ramathibodi hospital
    Kawamatawong, T.
    Treesinchai, W.
    Saelee, R.
    Tangchareon, T.
    Vathesatogkit, P.
    CHEST, 2017, 151 (05) : 28A - 28A
  • [4] Persistence to inhaled long-acting maintenance therapy in patients with COPD in UK routine clinical practice
    Rothnie, Kieran J.
    Wood, Robert P.
    Numbere, Beade
    Seif, Monica
    Requena, Gema
    Diomatari, Christina
    Goodall, Emma C.
    Noorduyn, Stephen G.
    Cooper, Charley
    Sharma, Raj
    Compton, Chris
    Ismaila, Afisi S.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [5] RISK FACTORS AND MORTALITY ASSOCIATED WITH DEVELOPING DIABETIC KETOACIDOSIS (DKA) IN PATIENTS HOSPITALIZED FOR COPD EXACERBATION
    Zaman, Mohammed
    Farooq, Awais
    Liaqat, Adnan
    Foster, Brian
    Tosto, Sebastian Thomas
    CHEST, 2022, 162 (04) : 1043A - 1043A
  • [6] Differences in COPD Exacerbation Risk Between Women and Men Analysis From the UK Clinical Practice Research Datalink Data
    Stolz, Daiana
    Kostikas, Konstantinos
    Loefroth, Emil
    Fogel, Robert
    Gutzwiller, Florian S.
    Conti, Valentino
    Cao, Hui
    Clemens, Andreas
    CHEST, 2019, 156 (04) : 674 - 684
  • [7] Increasing risk of exacerbation and mortality associated with increasing frequency and severity of exacerbations in COPD patients: EXACOS-UK
    Whittaker, Hannah
    Rubino, Annalisa
    Mullerova, Hana
    Morris, Tamsin
    Varghese, Precil
    Xu, Yang
    De Nigris, Enrico
    Quint, Jennifer K.
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [8] Health Status in Patients with COPD According, to GOLD 2017 Classification: Use of the COMCOLD Score in Routine Clinical Practice
    Figueira Goncalves, Juan Marco
    Martin Martinez, Maria Dolores
    Perez Mendez, Lina Inmaculada
    Garcia Bello, Miguel Angel
    Garcia-Talavera, Ignacio
    Garcia Hernandez, Sara
    Diaz Perez, David
    Bethencourt Martin, Natalia
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018, 15 (04) : 326 - 333
  • [9] Evaluation of the incidence and of risk factors associated with trastuzumab-associated cardiac toxicity in routine clinical practice
    Lemieux, J.
    Cote, M.
    Provencher, L.
    Simard, I.
    St-Pierre, C.
    Demers, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] COVID-19 incidence and hospitalization in routine clinical practice among COPD patients in England in 2020
    Rothnie, K.
    Tritton, T.
    Han, X.
    Holbrook, T.
    Numbere, B.
    Ford, A.
    Massey, L.
    Fu, Q.
    Hutchinson, F.
    Birch, H.
    Leather, D.
    Sharma, R.
    Compton, C.
    Ismaila, A.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60